Valuation: Genfit S.A.

Market Cap 543M 623M 512M 466M 874M 59.69B 875M 6.13B 2.36B 30.41B 2.34B 2.29B 98.12B P/E 2026 *
28x
P/E 2027 * 61.9x
Enterprise Value 492M 564M 464M 422M 791M 54.08B 792M 5.55B 2.14B 27.55B 2.12B 2.07B 88.89B EV / Sales 2026 *
5.25x
EV / Sales 2027 * 3.66x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Genfit S.A.

1 day+4.07%
Current year+44.59%
Current year 5.76
Extreme 5.76
10.2
1 year 3
Extreme 3
10.2
3 years 2.55
Extreme 2.55
10.2
5 years 2.55
Extreme 2.55
10.2
10 years 2.55
Extreme 2.55
26.25
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
+4.07%-.--% - - 623M
+1.77%+3.91%+3.22%+30.94% 46.68B
+1.30%+1.58%+44.15%+35.50% 44.42B
+0.95%-6.02%+342.72%+532.41% 41.32B
+4.23%+3.35%+9.35%+94.73% 41.58B
+1.11%+1.45%+11.52%+45.96% 30.14B
+1.94%+4.84%+25.19%+159.21% 17.42B
+0.37%-10.32% - - 15.6B
+0.67%+6.94%+25.37%+43.24% 15.54B
+0.24%+25.43%-11.57% - 14.08B
Average +1.15%+3.55%+56.24%+134.57% 29.64B
Weighted average by Cap. +0.89%+2.11%+70.38%+142.51%

Financials

2026 *2027 *
Net sales 93.77M 108M 88.32M 80.43M 151M 10.3B 151M 1.06B 408M 5.25B 404M 395M 16.94B 130M 149M 122M 111M 209M 14.27B 209M 1.46B 565M 7.27B 560M 547M 23.46B
Net income 28.97M 33.23M 27.29M 24.85M 46.59M 3.18B 46.65M 327M 126M 1.62B 125M 122M 5.23B 17.25M 19.78M 16.25M 14.8M 27.74M 1.9B 27.78M 195M 74.99M 966M 74.32M 72.67M 3.12B
Net Debt -51.11M -58.62M -48.13M -43.84M -82.19M -5.62B -82.29M -576M -222M -2.86B -220M -215M -9.23B -67.56M -77.48M -63.63M -57.95M -109M -7.42B -109M -762M -294M -3.78B -291M -285M -12.2B
Logo Genfit S.A.
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.86EUR
Average target price
18.10EUR
Spread / Average Target
+66.67%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!